ASH 2020: Results of a phase III study investigating Venetoclax combined with Obinutuzumab for first line treatment of CLL.
Home / Resource Library / Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial